Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis.

A similar trend was seen for HDL cholesterol from baseline to weeks 12 and 24, although the change did not reach statistical significance.

also in 111,027 other papers

However, while FMD improved on rituximab therapy at week 12, this improvement did not correlate with changes in disease activity, and a negative correlation was found with inflammatory markers that did not quite reach statistical significance.

also in 679 other papers